Since 2000, BMS has operated a multifaceted program designed to improve access to HIV/AIDS medicines in countries that are among the most significantly impacted by the pandemic and have the fewest resources to combat it. The program rests upon three pillars: (1) antiretroviral pricing that reflects no profit for the company in sub-Saharan Africa and low-income countries; an HIV/AIDS medicines patent policy that reflects a commitment to access through generic manufacturer participation in sub-Saharan Africa and India; and (3) partnering with others who share in a commitment to the fight against HIV/AIDS.
The goal of the Bristol-Myers Squibb Global Access Program is to enable broad access to our HIV medicines in regions most severely impacted by HIV and with limited ability to pay. Videx, Zerit and Reyataz are currently available through the Bristol-Myers Squibb Global Access Program.
At the same time, Bristol-Myers Squibb continue to focus our R&D efforts across a number of HIV/AIDS programs, and work with health care authorities worldwide to help ensure appropriate access to current therapies. Procurement groups that participate in the HIV Global ACCESS program include the Clinton Foundation, UNICEF, the International Development Authority, the Partnership for Supply Chain Management, Medecins Sans Frontieres and other global, regional and local organizations.
Bristol-Myers Squibb’s HIV Global ACCESS Program operates in more than 60 countries around the world in Africa, Asia, Latin America and the Middle East. The company also offers tiered pricing for HIV/AIDS products in middle-income countries.